The Oral Microbiome During Dupilumab or Upadacitinib Eczema Treatment

Research-focused microbiome review; not a treatment recommendation.

Why study the mouth in a skin disease?

The oral cavity is an immune-active microbial ecosystem. Researchers characterized oral microbiome profiles in people with atopic dermatitis treated with dupilumab or upadacitinib and compared microbial data with EASI severity.

Association does not define a gut–skin or mouth–skin pathway

Cross-sectional or small longitudinal differences can reflect age, diet, dental health, smoking, mouthwash, antibiotics, dry mouth, socioeconomic factors and medication. Even when a microbial pattern correlates with EASI, it may be a marker of shared inflammation rather than a driver of skin disease.

Different drugs create many comparison problems

People prescribed a biologic may differ from those prescribed an oral JAK inhibitor in prior treatment, comorbidities and clinician selection. Without randomization, between-group microbial differences cannot be attributed solely to drug mechanism. Multiple taxa comparisons also require careful control of false discovery.

What this does not support

The study does not justify antimicrobial mouthwash, oral probiotics or dental procedures as eczema treatment. Good oral hygiene remains important for general health, but product choice should follow dental guidance. Systemic medication decisions remain based on validated eczema outcomes and safety—not microbiome sequencing.

Infant relevance

These adult treatment observations do not apply to babies. Caregivers should not give probiotics or alter infant feeding to reproduce an adult microbiome result without pediatric advice.

Bottom line

Oral-microbiome research may help map systemic immune effects, but this study is exploratory and does not establish a therapeutic oral target for eczema.

Related Dr. Arsy research

• Choosing an eczema moisturizer
• Eczema and sleep research guide
• Childhood eczema and school performance
• Comparing eczema treatments
• Targeted-therapy tapering evidence
• Recognizing eczema across skin tones

References

1. Oral microbiome with dupilumab or upadacitinib
2. Systemic therapies and skin bacteriome pilot
3. Abrocitinib and the skin microbiome study
4. Topical Lactobacillus lactis pilot trial
5. Washed microbiota transplantation study
6. Qing-Re-Qu-Shi multi-omics randomized trial
7. Nature-based microbial exposure pilot
8. Child dupilumab skin and gut microbiome pilot
9. Pediatric skin-microbiome emollient trial
10. Pediatric gut and skin microbiota case-control study
11. XZ.700 endolysin randomized trial
12. Staphylococcus hominis A9 safety trial
13. B244 itch randomized trial
14. Farnesol moisturizer microbiome study
15. AAD topical therapy guideline
16. AAD systemic therapy guideline
17. AAAAI/ACAAI GRADE guideline
18. Atopic dermatitis microbiome review
19. Staphylococcus aureus and atopic dermatitis review
20. Skin microbiome in atopic dermatitis review
21. Dupilumab SOLO phase 3 trials
22. Upadacitinib Measure Up trials
23. Abrocitinib JADE MONO-1 trial
24. HOME core outcome set

Referenced researchers do not endorse Dr. Arsy products.